Healthcare Industry News: Vacuum Assisted Closure
News Release - February 2, 2009
KCI Announces That Court of Appeals Affirms Lower Court Ruling, Including Validity of NPWT PatentsSAN ANTONIO--(HSMN NewsFeed)--Kinetic Concepts, Inc. (NYSE: KCI ) announced today that the U.S. Court of Appeals for the Federal Circuit has upheld the validity of the two Wake Forest patents involved in the litigation against BlueSky Medical Group, Inc., Medela AG, and Medela, Inc. The Court also upheld the jury finding that the patent claims involved in the case are not infringed by the gauze-based Versatile 1 system marketed by BlueSky, which was acquired by Smith & Nephew in May 2007. The Wake Forest patents encompass numerous and varied claims related to KCI’s V.A.C.® technology used for the treatment of patients with serious, complex wounds.
“The Court’s decision confirms our belief that the fundamental intellectual property covering our revolutionary V.A.C.® technology is valid and enforceable,” said Catherine Burzik, KCI’s President and Chief Executive Officer. “KCI will continue to enforce its intellectual property rights which allow us to invest in new technologies that help millions of patients around the world. We remain committed to new product offerings and improvements in the areas of negative pressure and V.A.C. therapy, which we expect to launch in the coming months.”
Kinetic Concepts, Inc. (NYSE: KCI ) is a leading global medical technology company devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound care, tissue regeneration and therapeutic support system markets. Headquartered in San Antonio, Texas, KCI's success spans more than three decades and can be traced to a history deeply rooted in innovation and a passion for significantly improving the healing - and the lives - of patients around the world.
KCI's three primary businesses include:
Advanced Wound Care - Includes KCI's proprietary Vacuum Assisted Closure, or V.A.C. Therapy System, which has been clinically demonstrated to promote wound healing through unique mechanisms of action while reducing the overall cost of treating patients with complex wounds.
Regenerative Medicine - Represented by KCI's LifeCell business and includes tissue-based products for use in reconstructive, orthopedic and urogynecologic surgical procedures to repair soft tissue defects.
Therapeutic Support Systems - Includes specialty hospital beds, mattress replacement systems and overlays designed to address pulmonary complications associated with immobility, to reduce skin breakdown and assist caregivers in the safe and dignified handling of patients of size.
The company employs 7,000 people and markets its products in more than 20 countries. For more information about KCI, and how its products are changing the practice of medicine, visit www.KCI1.com.
This press release contains forward-looking statements regarding management’s expectations for the outcome of litigation and the company's future plans for the commercialization of new products. Forward-looking statements may contain words such as believes, expects, anticipates, estimates, projects, intends, should, seeks, future, continue, or the negative of such terms, or other comparable terminology. Forward-looking statements are subject to risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from those expressed in or indicated by them. Additional risks and factors are identified in KCI's filings with the U.S. Securities Exchange Commission (the SEC), including its Annual Report on Form 10-K for the fiscal year ending December 31, 2007 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, which are available on the SEC's Web site at http://www.sec.gov. KCI undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Kinetic Concepts
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.